Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	193	191	199	413	264	133
Market Cap Growth	9.33%	-4.09%	-51.84%	56.44%	98.01%	19.78%
Enterprise Value	152	151	134	349	228	101
Last Close Price	1.48	1.09	1.17	2.45	1.76	0.89
PE Ratio	-	-8.76	-7.56	-9.37	-12.79	-11.06
PS Ratio	24.07	21.32	13.53	95.13	144.57	37.93
PB Ratio	2.66	3.08	2.76	4.54	2.78	1.20
P/FCF Ratio	-11.81	-6.52	307.85	-17.28	-13.32	-4.12
P/OCF Ratio	-12.08	-6.68	187.79	-17.53	-13.36	-4.17
EV/Sales Ratio	19.02	16.88	9.11	80.50	124.70	28.82
EV/EBITDA Ratio	-11.94	-7.36	-6.15	-7.23	-9.33	-3.29
EV/EBIT Ratio	-11.55	-7.12	-5.95	-7.10	-8.61	-3.00
EV/FCF Ratio	-10.37	-5.17	207.31	-14.62	-11.49	-3.13
Debt / Equity Ratio	0.05	0.05	0.05	0.03	0.04	0.05
Debt / FCF Ratio	-0.14	-0.10	6.03	-0.12	-0.19	-0.16
Asset Turnover	0.07	0.08	0.10	0.03	0.02	0.03
Quick Ratio	2.59	2.02	3.06	2.32	5.35	4.78
Current Ratio	2.71	2.14	3.16	2.37	5.66	8.86
Return on Equity (ROE)	-33.76%	-32.07%	-32.37%	-46.52%	-20.05%	-11.62%
Return on Assets (ROA)	-11.97%	-11.80%	-9.44%	-21.78%	-14.16%	-18.59%
Return on Capital (ROIC)	-18.06%	-18.82%	-16.60%	-31.93%	-15.35%	-20.02%
Earnings Yield	-12.28%	-11.26%	-13.21%	-10.42%	-7.82%	-8.78%
FCF Yield	-12.27%	-15.33%	0.32%	-5.79%	-7.51%	-24.29%
Buyback Yield / Dilution	-7.51%	-1.69%	-3.22%	-9.64%	-3.10%	-14.68%
Total Shareholder Return	-7.51%	-1.69%	-3.22%	-9.64%	-3.10%	-14.68%

Source: S&P Capital IQ. Standard template.